LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Effect of pneumococcal conjugate vaccines on invasive pneumococcal disease - Authors' reply.

de Cunto Brandileone, Maria Cristina / Castañeda-Orjuela, Carlos / Almeida, Samanta Cristine Grassi / Andrade, Ana Lucia

The Lancet. Infectious diseases

2021 Volume 21, Issue 4, Page(s) 453–454

MeSH term(s)	Caribbean Region ; Child ; Humans ; Latin America ; Pneumococcal Infections/epidemiology ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines ; Retrospective Studies ; Vaccines, Conjugate
Chemical Substances	Pneumococcal Vaccines ; Vaccines, Conjugate
Language	English
Publishing date	2021-03-24
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	2061641-7
ISSN	1474-4457 ; 1473-3099
ISSN (online)	1474-4457
ISSN	1473-3099
DOI	10.1016/S1473-3099(21)00129-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5743: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Optimal age targeting for pneumococcal vaccination in older adults; a modelling study.

Nature communications

2023 Volume 14, Issue 1, Page(s) 888

Abstract: Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the population size benefiting from pneumococcal vaccines and robustness of immunogenic response to vaccination decline. We estimate how demographics, vaccine efficacy/ ... ...

Abstract	Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the population size benefiting from pneumococcal vaccines and robustness of immunogenic response to vaccination decline. We estimate how demographics, vaccine efficacy/effectiveness (VE), and waning VE impact on optimal age for a single-dose pneumococcal vaccination. Age- and vaccine-serotype-specific IPD cases from routine surveillance of adults ≥ 55 years old (y), ≥ 4-years after infant-pneumococcal vaccine introduction and before 2020, and VE data from prior studies were used to estimate IPD incidence and waning VE which were then combined in a cohort model of vaccine impact. In Brazil, Malawi, South Africa and England 51, 51, 54 and 39% of adults older than 55 y were younger than 65 years old, with a smaller share of annual IPD cases reported among < 65 years old in England (4,657; 20%) than Brazil (186; 45%), Malawi (4; 63%), or South Africa (134, 48%). Vaccination at 55 years in Brazil, Malawi, and South Africa, and at 70 years in England had the greatest potential for IPD prevention. Here, we show that in low/middle-income countries, pneumococcal vaccines may prevent a substantial proportion of residual IPD burden if administered earlier in adulthood than is typical in high-income countries.
MeSH term(s)	Infant ; Humans ; Aged ; Middle Aged ; Pneumococcal Infections/epidemiology ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines ; Vaccination ; Serogroup ; Incidence
Chemical Substances	Pneumococcal Vaccines
Language	English
Publishing date	2023-02-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-36624-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.

Ho, Yeh-Li / Brandão, Angela Pires / de Cunto Brandileone, Maria Cristina / Lopes, Marta Heloisa

Vaccine

2013 Volume 31, Issue 37, Page(s) 4047–4053

Abstract: Background: Streptococcus pneumoniae is a leading cause of hospitalization in HIV-infected adults therefore pneumococcal vaccine is recommended. The ideal antipneumococcal vaccine and effective vaccination regimen remain controversial and needs further ... ...

Abstract	Background: Streptococcus pneumoniae is a leading cause of hospitalization in HIV-infected adults therefore pneumococcal vaccine is recommended. The ideal antipneumococcal vaccine and effective vaccination regimen remain controversial and needs further evaluation. Methods: To assess the efficacy of pneumococcal vaccines alone and combined, a randomized, blinded clinical trial was conducted in Brazil with 331 HIV-patients aged 18-60, with CD4-T cell count ≥ 200 cells/mm(3). Two interventions 60 days apart were done in three schedules: 23-valent pneumococcal polysaccharide vaccine (PPV23)/placebo; 7-valent pneumococcal conjugate vaccine (PCV7)/placebo; and PCV7 plus PPV23. Safety and reactogenicity were evaluated, and immunogenicity was assessed by an IgG enzyme-linked immunosorbent assay to S. pneumoniae serotypes 6B, 9V and 14, performed at baseline, 60 and 180 days after first intervention. Comparison of immunogenicity was based on geometric mean concentration (GMC), percentages of individuals with serotype-specific IgG ≥ 0.35μg/mL and ≥ 1.0 μg/mL and proportion of individuals with ≥ 4-fold increase in specific antibody concentrations for each serotype. Results: Demographic and HIV conditions were similar, and both vaccines were well tolerated across vaccine groups. Significant increase in IgG-antibodies was observed to all serotypes evaluated. A greater proportion of PCV7 recipients reached and sustained IgG antibody concentrations at least four times as high as those at baseline, for serotypes 6B and 9V. A PPV23 dose after PCV7 did not enhance immunogenicity. Conclusions: In this first trial conducted with HIV-infected immunologically stable adults in South America, both PPV23 and PCV7 were safe and immunogenic. Evidence suggesting PCV7 was more immunogenic than PPV23, as it elicited higher and persistent ≥ 4-fold increase of antibodies for 6B and 9V serotypes in a greater proportion of HIV-patients is noteworthy. Despite current recommendation of schedules combining PCV7 and PPV23, there is little evidence to support this practice and we did not observe benefits in this combination.
MeSH term(s)	Adult ; Brazil ; Female ; HIV Infections ; Heptavalent Pneumococcal Conjugate Vaccine ; Humans ; Male ; Middle Aged ; Pneumococcal Vaccines/immunology ; Pneumococcal Vaccines/therapeutic use ; Vaccination ; Young Adult
Chemical Substances	23-valent pneumococcal capsular polysaccharide vaccine ; Heptavalent Pneumococcal Conjugate Vaccine ; Pneumococcal Vaccines
Language	English
Publishing date	2013-08-20
Publishing country	Netherlands
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2013.04.065
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.

Andrade, Ana Lucia / Minamisava, Ruth / Tomich, Lisia Moura / Lemos, Ana Paula / Gorla, Maria Cecilia / de Cunto Brandileone, Maria Cristina / Domingues, Carla Madga S / de Moraes, Camile / Policena, Gabriela / Bierrenbach, Ana Luiza

Vaccine

2017 Volume 35, Issue 16, Page(s) 2025–2033

Abstract: Background: Routine infant immunization with meningococcal C conjugate (MCC) vaccination started in Brazil in November 2010, scheduled at three and five months plus a booster at 12-15months of age. No catch-up was implemented. We assessed the impact of ... ...

Abstract	Background: Routine infant immunization with meningococcal C conjugate (MCC) vaccination started in Brazil in November 2010, scheduled at three and five months plus a booster at 12-15months of age. No catch-up was implemented. We assessed the impact of vaccination on meningococcal C disease (MenC) four years after vaccination start in the National Immunization Program. Methods: We performed an ecological quasi-experimental design from 2008 to 2014 using a deterministic linkage between the National Notification and the National Reference Laboratory databases for meningitis. We conducted an interrupted time-series analysis considering Brazil except for Salvador municipality, because an epidemic of serogroup C disease occurred in this city, which prompted a mass vaccination campaign with catch-up for adolescents in 2010. Observed MenC rates in the post-vaccination period were compared to expected rates calculated from the pre-vaccination years. Results for Salvador were presented as descriptive data. An additional time-series analysis was performed for the state of São Paulo. Results: A total of 18,136 MenC cases were analyzed. The highest incidence rates were observed for infants aged <12months and no second incident peak was observed for adolescents. For Brazil, MenC rates were reduced by 67.2% (95%CI 43.0-91.4%) for infants <12months of age, 92.0% (77.3-106.8%) for the age-group 12-23months, and 64.6% (24.6-104.5%) for children aged 2-4years. For children 5-9years old, MenC rates reduced 19.2% (9.5-28.9%). Overall, 955 MenC cases were averted in Brazil in individuals aged <40years after MCC vaccination. Results from São Paulo State, mirror the patterns seen in Brazil. Conclusion: After four years of infants and toddlers vaccination start, MenC invasive disease reduced in the target population. This investigation provide a robust baseline to ascertain how much the upcoming catch-up dose in 12-13years of age will accelerate the decrease in MenC incidence rates among youths in Brazil.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Brazil/epidemiology ; Child ; Child, Preschool ; Female ; Humans ; Incidence ; Infant ; Male ; Meningitis, Meningococcal/epidemiology ; Meningitis, Meningococcal/prevention & control ; Meningococcal Vaccines/administration & dosage ; Meningococcal Vaccines/immunology ; Middle Aged ; Neisseria meningitidis, Serogroup C/immunology ; Neisseria meningitidis, Serogroup C/isolation & purification ; Non-Randomized Controlled Trials as Topic ; Young Adult
Chemical Substances	Meningococcal Vaccines
Language	English
Publishing date	2017--11
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2017.03.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.

Andrade, Ana Lucia / Minamisava, Ruth / Policena, Gabriela / Cristo, Elier B / Domingues, Carla Magda S / de Cunto Brandileone, Maria Cristina / Almeida, Samanta Cristine Grassi / Toscano, Cristiana Maria / Bierrenbach, Ana Luiza

Human vaccines & immunotherapeutics

2016 Volume 12, Issue 2, Page(s) 285–292

Abstract: Routine infant immunization with 10-valent pneumococcal conjugate vaccine (PCV-10) began in Brazil in 2010. The impact of the PCV-10 on rates of invasive pneumococcal disease (IPD) at the population level was not yet evaluated. Serotype-specific IPD ... ...

Abstract	Routine infant immunization with 10-valent pneumococcal conjugate vaccine (PCV-10) began in Brazil in 2010. The impact of the PCV-10 on rates of invasive pneumococcal disease (IPD) at the population level was not yet evaluated. Serotype-specific IPD changes after PCV-10 introduction is still to be determined. Data from national surveillance system for notifiable diseases (SINAN) and national reference laboratory for S. pneumoniae in Brazil (IAL) were linked to enhance case ascertainment of IPD. An interrupted time-series analysis was conducted to predict trends in the postvaccination IPD rates in the absence of PCV-10 vaccination, taking into consideration seasonality and secular trends. PCVs serotype-specific distribution were assessed before (2008-2009) and after (2011-2013) the introduction of PCV-10 in the immunization program. A total of 9,827 IPD cases were identified from 2008-2013 when combining SINAN and IAL databases. Overall, PCV-10 types decreased by 41.3% after PCV-10 vaccination period, mostly in children aged 2-23 months, while additional PCV-13 serotypes increased by 62.8% mainly in children under 5-year of age. For children aged 2-23 months, targeted by the immunization program, we observed a 44.2% (95%CI, 15.8-72.5%) reduction in IPD rates. In contrast, significant increase in IPD rates were observed for adults aged 18-39 y (18.9%, 95%CI 1.1-36.7%), 40-64 y (52.5%, 95%CI 24.8-80.3%), and elderly ≥ 65 y (79.3%, 95%CI 62.1-96.5%). This is the first report of a time-series analysis for PCV impact in IPD conducted at national level data in a developing country. We were able to show significant impact of PCV-10 on IPD for age groups targeted by vaccination in Brazil, 3 y after its introduction. No impact on other age groups was demonstrated.
MeSH term(s)	Adolescent ; Adult ; Brazil/epidemiology ; Child ; Child, Preschool ; Humans ; Immunization Programs ; Immunologic Deficiency Syndromes/epidemiology ; Immunologic Deficiency Syndromes/microbiology ; Immunologic Deficiency Syndromes/prevention & control ; Infant ; Meningitis, Pneumococcal/epidemiology ; Meningitis, Pneumococcal/microbiology ; Meningitis, Pneumococcal/prevention & control ; Middle Aged ; Pneumococcal Infections/epidemiology ; Pneumococcal Infections/microbiology ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines/immunology ; Serogroup ; Streptococcus pneumoniae/immunology ; Vaccination ; Vaccines, Conjugate/immunology ; Young Adult
Chemical Substances	10-valent pneumococcal conjugate vaccine ; 13-valent pneumococcal vaccine ; Pneumococcal Vaccines ; Vaccines, Conjugate
Language	English
Publishing date	2016
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2664176-8
ISSN	2164-554X ; 2164-5515
ISSN (online)	2164-554X
ISSN	2164-5515
DOI	10.1080/21645515.2015.1117713
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6967: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.

Domingues, Carla Magda Allan S / Verani, Jennifer R / Montenegro Renoiner, Ernesto Issac / de Cunto Brandileone, Maria Cristina / Flannery, Brendan / de Oliveira, Lucia Helena / Santos, João Barberino / de Moraes, José Cássio

The Lancet. Respiratory medicine

2014 Volume 2, Issue 6, Page(s) 464–471

Abstract: Background: In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven-valent vaccine. The schedule comprised ... ...

Abstract	Background: In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven-valent vaccine. The schedule comprised three primary doses at ages 2 months, 4 months, and 6 months, and a booster dose at age 12 months. A single catch-up dose was offered for children aged 12-23 months at the time of introduction. We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children. Methods: Invasive pneumococcal disease, defined as isolation of Streptococcus pneumoniae from blood, cerebrospinal fluid, or another normally sterile site, was identified in children age-eligible for at least one PCV10 dose through laboratory-based and hospital-based surveillance in ten states in Brazil from March 1, 2010, until Dec 31, 2012. We aimed to identify four age-matched and neighbourhood-matched controls for each case. We used conditional logistic regression and calculated PCV10 effectiveness as (1-adjusted matched odds ratio) × 100% for vaccine-type and vaccine-related serotypes (ie, in the same serogroup as a vaccine serotype). Findings: In 316 cases (median age 13·2 months, range 2·6-53·1) and 1219 controls (13·3 months, 2·6-53·1), the adjusted effectiveness of an age-appropriate PCV10 schedule was 83·8% (95% CI 65·9-92·3) against vaccine serotypes, and 77·9% (41·0-91·7) against vaccine-related serotypes. Serotype-specific effectiveness was shown for the two most common vaccine serotypes-14 (87·7%, 60·8-96·1) and 6B (82·8%, 23·8-96·1)-and serotype 19A (82·2%, 10·7-96·4), a serotype related to vaccine serotype 19F. A single catch-up dose in children aged 12-23 months was effective against vaccine-type disease (68·0%, 17·6-87·6). No significant effectiveness was shown against non-vaccine serotypes for age-appropriate or catch-up schedules. Interpretation: In the routine immunisation programme in Brazil, PCV10 prevents invasive disease caused by vaccine serotypes. PCV10 might provide cross-protection against some vaccine-related serotypes. Funding: Brazilian Ministry of Health, Pan-American Health Organization, and US Centers for Disease Control and Prevention.
MeSH term(s)	Brazil/epidemiology ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Incidence ; Infant ; Male ; Pneumococcal Infections/epidemiology ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines/therapeutic use ; Prevalence ; Retrospective Studies ; Streptococcus pneumoniae/immunology ; Vaccines, Conjugate
Chemical Substances	10-valent pneumococcal conjugate vaccine ; Pneumococcal Vaccines ; Vaccines, Conjugate
Language	English
Publishing date	2014-04-10
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	2686754-0
ISSN	2213-2619 ; 2213-2600
ISSN (online)	2213-2619
ISSN	2213-2600
DOI	10.1016/S2213-2600(14)70060-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7041: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.

Brandão, Angela Pires / de Oliveira, Tânia Cristina / de Cunto Brandileone, Maria Cristina / Gonçalves, Jorge Emílio / Yara, Teresa Ikuko / Simonsen, Vera

Vaccine

2004 Volume 23, Issue 6, Page(s) 762–768

Abstract: To evaluate the immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 52 nursing homes residents aged > or = 60 years, IgG antibodies to serotypes 1, 5, 6B, and 8 were measured by ELISA and compared before, and 1 and 12 months following ... ...

Abstract	To evaluate the immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 52 nursing homes residents aged > or = 60 years, IgG antibodies to serotypes 1, 5, 6B, and 8 were measured by ELISA and compared before, and 1 and 12 months following vaccination. A significant immunological response for all serotypes was observed at 1 month after vaccination. The mean increase in antibody concentration was highly variable and ranged from 1.6 to 2.7. After 1 year, the mean concentrations remained significantly higher than prior to vaccination for serotypes 1, 6B, and 8, although there was a decrease in all mean IgG concentrations. Antibody levels were higher in men than in women, before and after immunisation. Post-vaccination values tended to be lower among subjects aged >75 years. Reduction in IgG concentrations by 33% 1 year after vaccination suggests that revaccination of institutionalised elderly people may be needed.
MeSH term(s)	Aged ; Antibodies, Bacterial/blood ; Humans ; Immunoglobulin G/immunology ; Middle Aged ; Pneumococcal Infections/immunology ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines/administration & dosage ; Pneumococcal Vaccines/immunology ; Polysaccharides, Bacterial/immunology ; Vaccination
Chemical Substances	Antibodies, Bacterial ; Immunoglobulin G ; Pneumococcal Vaccines ; Polysaccharides, Bacterial
Language	English
Publishing date	2004-12-21
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2004.07.024
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Survey of nonsusceptible nasopharyngeal Streptococcus pneumoniae isolates in children attending day-care centers in Brazil.

Franco, Caritas M / Andrade, Ana Lucia S / Andrade, João G / Almeida e Silva, Simonne / Oliveira, C Renato M / Pimenta, Fabiana C / Lamaro-Cardoso, Juliana / Brandão, Angela P / Almeida, Samanta C G / Calix, Juan J / Nahm, Moon H / de Cunto Brandileone, Maria-Cristina

The Pediatric infectious disease journal

2010 Volume 29, Issue 1, Page(s) 77–79

Abstract: A survey of nasopharyngeal carriage of penicillin nonsusceptible pneumococcal (PNSp) isolates was conducted among 1192 children attending 62 day care centers in Brazil, where pneumococcal vaccination has not been routinely introduced. Nasopharyngeal ... ...

Abstract	A survey of nasopharyngeal carriage of penicillin nonsusceptible pneumococcal (PNSp) isolates was conducted among 1192 children attending 62 day care centers in Brazil, where pneumococcal vaccination has not been routinely introduced. Nasopharyngeal pneumococcal carriage was detected in 686 (57.6%) infants, and 178 (25.9%) of them carried PNSp isolates. Being less than 24 months of age, hospitalization in the previous 3 months, and recurrent acute otitis media were independently associated with PNSp. Serotypes 14, 23F, 19A, 6A, 6B and 19F were the most common serotype isolated accounting for 80% of the PNSp. A high proportion (35/332) of non-(sero)typeable isolates was detected, 62.9% of them PNSp. Serotypes coverage projected for the pneumococcal conjugate vaccine (PCV) 13-valent vaccine (72%) was significantly higher compared with PCV7 (58.4%) and PCV 10-valent vaccine (59.3%).
MeSH term(s)	Bacterial Typing Techniques ; Brazil/epidemiology ; Carrier State/epidemiology ; Carrier State/microbiology ; Child Day Care Centers ; Child, Preschool ; Cross-Sectional Studies ; Female ; Hospitalization/statistics & numerical data ; Humans ; Infant ; Male ; Nasopharynx/microbiology ; Otitis Media/epidemiology ; Penicillin Resistance ; Pneumococcal Infections/epidemiology ; Pneumococcal Infections/microbiology ; Prevalence ; Recurrence ; Serotyping ; Streptococcus pneumoniae/classification ; Streptococcus pneumoniae/drug effects ; Streptococcus pneumoniae/isolation & purification
Language	English
Publishing date	2010-01-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	392481-6
ISSN	1532-0987 ; 0891-3668
ISSN (online)	1532-0987
ISSN	0891-3668
DOI	10.1097/INF.0b013e3181af7e90
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1852: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil

Ho, Yeh-Li / Brandão, Angela Pires / de Cunto Brandileone, Maria Cristina / Lopes, Marta Heloisa

Vaccine

Volume v. 31,, Issue no. 3

Abstract: BACKGROUND: Streptococcus pneumoniae is a leading cause of hospitalization in HIV-infected adults therefore pneumococcal vaccine is recommended. The ideal antipneumococcal vaccine and effective vaccination regimen remain controversial and needs further ... ...

Abstract	BACKGROUND: Streptococcus pneumoniae is a leading cause of hospitalization in HIV-infected adults therefore pneumococcal vaccine is recommended. The ideal antipneumococcal vaccine and effective vaccination regimen remain controversial and needs further evaluation. METHODS: To assess the efficacy of pneumococcal vaccines alone and combined, a randomized, blinded clinical trial was conducted in Brazil with 331 HIV-patients aged 18–60, with CD4-T cell count ≥200cells/mm³. Two interventions 60 days apart were done in three schedules: 23-valent pneumococcal polysaccharide vaccine (PPV23)/placebo; 7-valent pneumococcal conjugate vaccine (PCV7)/placebo; and PCV7 plus PPV23. Safety and reactogenicity were evaluated, and immunogenicity was assessed by an IgG enzyme-linked immunosorbent assay to S. pneumoniae serotypes 6B, 9V and 14, performed at baseline, 60 and 180 days after first intervention. Comparison of immunogenicity was based on geometric mean concentration (GMC), percentages of individuals with serotype-specific IgG≥0.35μg/mL and ≥1.0μg/mL and proportion of individuals with ≥4-fold increase in specific antibody concentrations for each serotype. RESULTS: Demographic and HIV conditions were similar, and both vaccines were well tolerated across vaccine groups. Significant increase in IgG-antibodies was observed to all serotypes evaluated. A greater proportion of PCV7 recipients reached and sustained IgG antibody concentrations at least four times as high as those at baseline, for serotypes 6B and 9V. A PPV23 dose after PCV7 did not enhance immunogenicity. CONCLUSIONS: In this first trial conducted with HIV-infected immunologically stable adults in South America, both PPV23 and PCV7 were safe and immunogenic. Evidence suggesting PCV7 was more immunogenic than PPV23, as it elicited higher and persistent ≥4-fold increase of antibodies for 6B and 9V serotypes in a greater proportion of HIV-patients is noteworthy. Despite current recommendation of schedules combining PCV7 and PPV23, there is little evidence to support this practice and we did not observe benefits in this combination.
Keywords	vaccines ; Streptococcus pneumoniae ; serotypes ; HIV infections ; CD4-positive T-lymphocytes ; immunoglobulin G ; antibodies ; adults ; immune response ; clinical trials ; vaccination ; enzyme-linked immunosorbent assay
Language	English
Document type	Article
ISSN	0264-410X
Database	AGRIS - International Information System for the Agricultural Sciences and Technology

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED